Takeda Unit Can't Undo $155M Loss In Bayer IP Row
A Delaware federal judge on Friday denied a bid from a Takeda Pharmaceutical unit to throw out a jury's verdict saying the company owes $155 million for infringing Bayer's hemophilia treatment...To view the full article, register now.
Already a subscriber? Click here to view full article